+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Myelogenous Leukemia Treatment - Global Market Trajectory & Analytics

  • ID: 5309907
  • Report
  • April 2021
  • Region: Global
  • 171 pages
  • Global Industry Analysts, Inc
Global Chronic Myelogenous Leukemia Treatment Market to Reach $7.6 Billion by 2027

Amid the COVID-19 crisis, the global market for Chronic Myelogenous Leukemia Treatment estimated at US$5.3 Billion in the year 2020, is projected to reach a revised size of US$7.6 Billion by 2027, growing at a CAGR of 5.3% over the period 2020-2027. Disease Specific Treatment, one of the segments analyzed in the report, is projected to record 5.9% CAGR and reach US$2.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Symptomatic Treatment segment is readjusted to a revised 5% CAGR for the next 7-year period.



The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 4.9% CAGR

The Chronic Myelogenous Leukemia Treatment market in the U.S. is estimated at US$1.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Select Competitors (Total 42 Featured):
  • Bio-Path Holdings, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Incyte Corporation
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Chronic Myelogenous Leukemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Disease Specific Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Disease Specific Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Disease Specific Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Symptomatic Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Branded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Branded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Branded by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 16: USA Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 17: USA Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 18: USA 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
  • Table 19: USA Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 20: USA Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 21: USA 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
  • CANADA
  • Table 22: Canada Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 23: Canada Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 24: Canada 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
  • Table 25: Canada Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: Canada Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 27: Canada 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
  • JAPAN
  • Table 28: Japan Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 29: Japan Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 30: Japan 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
  • Table 31: Japan Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: Japan Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 33: Japan 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
  • CHINA
  • Table 34: China Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 35: China Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 36: China 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
  • Table 37: China Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: China Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 39: China 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
  • EUROPE
  • Table 40: Europe Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 41: Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 42: Europe 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 43: Europe Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 45: Europe 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
  • Table 46: Europe Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 47: Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 48: Europe 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
  • FRANCE
  • Table 49: France Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: France Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 51: France 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
  • Table 52: France Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 53: France Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 54: France 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
  • GERMANY
  • Table 55: Germany Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: Germany Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 57: Germany 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
  • Table 58: Germany Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 59: Germany Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 60: Germany 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
  • ITALY
  • Table 61: Italy Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 62: Italy Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 63: Italy 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
  • Table 64: Italy Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 65: Italy Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 66: Italy 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
  • Table 67: UK Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 68: UK Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 69: UK 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
  • Table 70: UK Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 71: UK Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 72: UK 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
  • REST OF EUROPE
  • Table 73: Rest of Europe Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 74: Rest of Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 75: Rest of Europe 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
  • Table 76: Rest of Europe Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 77: Rest of Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 78: Rest of Europe 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
  • Table 79: Asia-Pacific Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 80: Asia-Pacific Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 81: Asia-Pacific 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
  • Table 82: Asia-Pacific Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 83: Asia-Pacific Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 84: Asia-Pacific 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
  • REST OF WORLD
  • Table 85: Rest of World Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 86: Rest of World Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 87: Rest of World 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
  • Table 88: Rest of World Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 89: Rest of World Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 90: Rest of World 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 42
Note: Product cover images may vary from those shown
Adroll
adroll